Patent · US Active

Rapidly disintegrating solid oral dosage forms containing dasatinib

US11833249B2 · kind B2 · utility

0Cited by

10References

12Claims

0Family size

Assignee

XSPRAY PHARMA AB · SE

Inventors

Per Andersson · Uppsala, SE
Thomas MEIJER · Viken, SE
Victor Söderberg · Uppsala, SE

Key dates

Filing date	May 6, 2022
Grant date	Dec 5, 2023
Priority date	—
Expiry date	May 24, 2042

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/506
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The instant application relates to the field of pharmaceutical compositions comprising dasatinb. Furthermore, the instant application relates to a method of treating proliferative disorders in a patient in need thereof, comprising administering a therapeutically effective amount of said compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.